Steinar Aamdal
Oslo, 0315, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Journal: International journal of molecular sciences
Published: May 02, 2022
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Journal: Journal for immunotherapy of cancer
Published: April 14, 2022
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.
Journal: ESMO open
Published: February 12, 2022
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
Journal: The Prostate
Published: July 12, 2021
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Journal: International journal of cancer
Published: May 07, 2021
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Journal: Frontiers in immunology
Published: February 03, 2021
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Journal: Frontiers in immunology
Published: June 12, 2020
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
Journal: Clinical and experimental immunology
Published: February 20, 2019
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 08, 2017
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 01, 2017
Acute liver graft rejection after ipilimumab therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 30, 2017
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.
Journal: Oncoimmunology
Published: August 22, 2016
Last Updated: 09/26/2026